FDA approves Corcept Therapeutics’ Lifyorli for certain cancers

The Food and Drug Administration approved relacorilant, or Lifyorli, from Corcept Therapeutics (CORT), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel, for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab, the agency announced.